Critical appraisal of ticagrelor in the management of acute coronary syndrome

References

• DibCHannaEAbu-FadelMA new era for antiplatelet therapy in patients with acute coronary syndromeAm J Med Sci201034040741120818228
   PubMed Web of Science ®Google Scholar
• MarczewskiMMPostulaMDariuszKNovel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelorVasc Health Risk Manag2010641942920539844
   PubMedGoogle Scholar
• Antiplatelet Trialists’ CollaborationCollaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ1994308811068298418
   PubMed Web of Science ®Google Scholar
• KushnerFGHandMSmithSC2009 focused updates: ACC/ AHA Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionJ Am Coll Cardiol2009542205224119942100
   PubMed Web of Science ®Google Scholar
• WrightRSAndersonJLAdamsCD2011ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarctionJ Am Coll Cardiol2011571920195921450428
   PubMed Web of Science ®Google Scholar
• The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial InvestigatorsEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med200134549450211519503
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJGEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet200135852753311520521
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med20073572001201517982182
   PubMed Web of Science ®Google Scholar
• CattaneoMP2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agentsEur Heart J2006271010101216569650
   PubMed Web of Science ®Google Scholar
• HustedSvan GiezenJJJTicagrelor: The first reversibly binding oral P2Y12 receptor antagonistCardiovasc Ther20092725927419604248
   PubMed Web of Science ®Google Scholar
• SerebruanyVLAdenosine release: A potential explanation for the benefits of ticagrelor in the PLATelet Inhibition and Clinical Outcomes trialAm Heart J20111611421167333
   PubMed Web of Science ®Google Scholar
• HammondJRStolkMArcherRGPharmacological analysis and molecular cloning of the canine equilibrative nucleoside transporter 1Eur J Pharmacol200449191915102528
   PubMed Web of Science ®Google Scholar
• Van GiezenJJSidawayJGlavesPTicagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine modelJ Cardiovasc Pharmacol Ther6222011 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• TengROliverSHayesMAbsorption, distribution, metabolism, and excretion of ticagrelor in healthy subjectsDrug Metab Dispos2010381514152120551239
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPButlerKRandomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET StudyCirculation20091202577258519923168
   PubMed Web of Science ®Google Scholar
• TengRButlerKPharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjectsEur J Clin Pharmacol20106648749620091161
   PubMed Web of Science ®Google Scholar
• HustedSEmanuelssonHHeptinstallSPharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirinEur Heart J2006271038104716476694
   PubMed Web of Science ®Google Scholar
• ThebaultJJKeifferGLoweGDRepeated-dose pharmacodynamics of clopidogrel in healthy subjectsSemin Thromb Hemost199925Suppl 291410440416
   PubMed Web of Science ®Google Scholar
• ZhouDAnderssonTBGrimmSWIn vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kineticsDrug Metab Dispos20113970371021177984
   PubMed Web of Science ®Google Scholar
• Brilinta prescribing informationWilmington, DEAstraZeneca2011
   Google Scholar
• ButlerKTengRPharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairmentJ Clin Pharmacol20115197898720926753
   PubMed Web of Science ®Google Scholar
• StoreyRFAngiolilloDJPatilSBInhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromesJ Am Coll Cardiol2010561456146220832963
   PubMed Web of Science ®Google Scholar
• GurbelPACummingsCCBellCRAlfordABMeisterAFSerebruanyVLOnset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary artery stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trialAm Heart J200314523924712595840
   PubMed Web of Science ®Google Scholar
• StoreyRFHustedSHarringtonRAInhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromesJ Am Coll Cardiol2007501852185617980251
   PubMed Web of Science ®Google Scholar
• StoreyRFBlidenKPEcobREarlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responsesJ Thromb Haemost201191730173721707911
   PubMed Web of Science ®Google Scholar
• Plavix prescribing informationBridgewater, NJBristol-Myers Squibb/ Sanofi Pharmaceuticals Partnership2011
   Google Scholar
• CannonCPHustedSHarringtonRASafety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-elevation acute coronary syndromeJ Am Coll Cardiol20075018441851 Erratum inJ Am Coll Cardiol. 2007;50:219617980250
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med20093611045105719717846
   PubMed Web of Science ®Google Scholar
• StegPGJamesSHarringtonRATicagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention. A Platelet Inhibition and Patient Outcomes (PLATO) Trial subgroup analysisCirculation20101222131214121060072
   PubMed Web of Science ®Google Scholar
• JamesSKRoeMTCannonCPTicagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trialBMJ2011342d352721685437
   PubMed Web of Science ®Google Scholar
• CannonCPHarringtonRAJamesSComparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind studyLancet201037528329320079528
   PubMed Web of Science ®Google Scholar
• HeldCÅsenbladNBassandJPTicagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. Results from the PLATO Platelet Inhibition and Patient Outcomes TrialJ Am Coll Cardiol20115767268421194870
   PubMed Web of Science ®Google Scholar
• JamesSAngiolilloDJCornelJHTicagrelor versus clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trialEur Heart J2010313006301620802246
   PubMed Web of Science ®Google Scholar
• JamesSBudajAAylwardPTicagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trialCirculation20101221056106720805430
   PubMed Web of Science ®Google Scholar
• MahaffeyKWWojdylaDMCarrollKTicagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) TrialCirculation201112454455421709065
   PubMed Web of Science ®Google Scholar
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared with Placebo on a Background of Aspirin (PEGASUS) Available at: http://clinicaltrials.gov/ct2/show/ NCT01225562Accessed September 23, 2011
   Google Scholar
• StoreyRFBlidenKPPatilSBIncidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET studyJ Am Coll Cardiol20105618519320620737
   PubMed Web of Science ®Google Scholar
• StoreyRFBeckerRCHarringtonRACharacterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomesEur Heart J7302011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• StoreyRFBeckerRCHarringtonRAPulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy)Am J Cardiol932011 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• BurkiNKDaleWJLeeLYIntravenous adenosine and dyspnea in humansJ Appl Physiol20059818018515377651
   PubMed Web of Science ®Google Scholar
• SciricaBMCannonCPEmanuelssonHThe incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial. Results of the continuous electrocardiographic assessment substudyJ Am Coll Cardiol2011571908191621545948
   PubMed Web of Science ®Google Scholar
• SerebruanyVLThe TRITON versus PLATO trials: Differences beyond platelet inhibitionThromb Haemost201010325926120024505
   PubMed Web of Science ®Google Scholar
• KreutzRPStanekEJAubertRImpact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the Clopidogrel Medco Outcomes StudyPharmacotherapy20103078779620653354
   PubMed Web of Science ®Google Scholar
• BhattDLCryerBLContantCFClopidogrel with or without omeprazole in coronary artery diseaseN Engl J Med20103631909191720925534
   PubMed Web of Science ®Google Scholar
• WarnerTDArmstrongPCJCurzenNPMitchellJADual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?Heart2010961693169420956485
   PubMed Web of Science ®Google Scholar
• SerebruanyVLAspirin dose and ticagrelor benefit in PLATO: fact or fictionCardiology201011728028321304245
   PubMed Web of Science ®Google Scholar
• KirkbyNSLeadbeaterPDMChanMVNylanderSMitchellJAWarnerTDAnti-platelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrelJ Thromb Haemost832011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• MomaryKMDorschMPBatesERGenetic causes of clopidogrel nonresponsiveness: which ones really countPharmacotherapy20103026527420180610
   PubMed Web of Science ®Google Scholar
• MalekLAKisielBSpiewakMCoexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrelCirc J2008721165116918577829
   PubMed Web of Science ®Google Scholar
• HulotJ-SColletJ-PSilvainJCardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. A systematic metaanalysisJ Am Coll Cardiol20105613414320620727
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPButlerKResponse to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies. The RESPOND studyCirculation20101211188119920194878
   PubMed Web of Science ®Google Scholar
• TantryUSBlidenKPWeiCFirst analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel. The ONSET/OFFSET and RESPOND genotype studiesCirc Cardiovasc Genet2010355656621079055
   PubMed Web of Science ®Google Scholar
• WallentinLJamesSStoreyRFEffect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcome of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialLancet20103761320132820801498
   PubMed Web of Science ®Google Scholar
• HenrikssonMNikolicEJanzonMLong-term costs and health outcomes of treating acute coronary syndrome patients with ticagrelor based on the EU label – cost-effectiveness analysis based on the PLATO study [abstract]Value Health201114A40 Available from: http://www.astrazeneca.com/Media/Press-releases/Article/09052011-new-health-study-of-plato-brilique-with-clopidogrelAccessed September 23, 2011
   Web of Science ®Google Scholar
• CrespinDJFederspielJJBiddleAKJonasDERossiJSTicagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysisValue Health20111448349121669373
   PubMed Web of Science ®Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther2001231296131011558866
   PubMed Web of Science ®Google Scholar
• Effient prescribing informationIndianapolis, INEli Lilly and Company2010
   Google Scholar
• WiviottSDTrenkDFrelingerALPRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation20071162923293218056526
   PubMed Web of Science ®Google Scholar
• Biondi-ZoccaiGLotrionteMAgostoniPAdjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromesInt J Cardiol201015032533120828843
   PubMed Web of Science ®Google Scholar
• MehranRRaoSVBhattDLStandardized bleeding definitions for cardiovascular clinical trials. A consensus report from the Bleeding Academic Research ConsortiumCirculation20111232736274721670242
   PubMed Web of Science ®Google Scholar
• The Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug AdministrationPrasugrel secondary review Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM181185.pdfAccessed September 23, 2011
   Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic and clinical outcomesCirculation20091192553256019414633
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDGenetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysisLancet20103761312131920801494
   PubMed Web of Science ®Google Scholar